Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × Irinotecan × 30 days × Clear all

Sponsor

Conditions

Colorectal Neoplasms 8 Neoplasm Metastasis 6 Sarcoma, Ewing 5 Pancreatic Neoplasms 5 Rhabdomyosarcoma 4 Colonic Neoplasms 4 Rectal Neoplasms 3 Wilms Tumor 2 Uterine Cervical Neoplasms 2 Pathologic Complete Response 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Osteosarcoma 2 Neuroblastoma 2 Neoplasms 2 Medulloblastoma 2 Esophageal Squamous Cell Carcinoma 2 Esophageal Neoplasms 2 Ependymoma 2 Endometrial Neoplasms 2 Colorectal Adenocarcinoma 2 Adenocarcinoma Of Esophagus 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Stage I Mixed Cell Type Kidney Wilms Tumor 1 Sarcoma 1 Rhabdomyosarcoma, Embryonal 1 Rhabdomyosarcoma, Alveolar 1 Rhabdoid Tumor 1 Recurrence 1

Interventions

pasireotide 1 E-7386 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡